Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro.
about
Hemopressin and other bioactive peptides from cytosolic proteins: are these non-classical neuropeptides?Cathepsin L plays an important role in the lysosomal degradation of L-lactate dehydrogenaseMurine cathepsin F deficiency causes neuronal lipofuscinosis and late-onset neurological disease.Increased serum cathepsin K in patients with coronary artery disease.Proteolysis sensitizes LDL particles to phospholipolysis by secretory phospholipase A2 group V and secretory sphingomyelinase.Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneasThe expression and activity of cathepsins D, H and K in asthmatic airways.Modified lipoprotein-derived lipid particles accumulate in human stenotic aortic valves.Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases.Peroxisome proliferator-activated receptor gamma induces apoptosis and inhibits autophagy of human monocyte-derived macrophages via induction of cathepsin L: potential role in atherosclerosis.Cysteine Protease Cathepsins in Atherosclerosis and Abdominal Aortic Aneurysm.Enzymatically Modified Low-Density Lipoprotein Promotes Foam Cell Formation in Smooth Muscle Cells via Macropinocytosis and Enhances Receptor-Mediated Uptake of Oxidized Low-Density Lipoprotein.Enhanced wound healing, kinase and stem cell marker expression in diabetic organ-cultured human corneas upon MMP-10 and cathepsin F gene silencing.Cysteine cathepsins in neurological disorders.Acidification of the intimal fluid: the perfect storm for atherogenesisCysteine proteases in atherosclerosis.The propeptide of cruzipain--a potent selective inhibitor of the trypanosomal enzymes cruzipain and brucipain, and of the human enzyme cathepsin F.Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents.Thermal stability of human plasma electronegative low-density lipoprotein: A paradoxical behavior of low-density lipoprotein aggregation.Low density lipoprotein aged in plasma forms clusters resembling subendothelial droplets: aggregation via surface sites.Clinical utility of serum cystatin C in predicting coronary artery disease in patients without chronic kidney disease.Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation.Decrease in pH strongly enhances binding of native, proteolyzed, lipolyzed, and oxidized low density lipoprotein particles to human aortic proteoglycans.Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases.Impact of circulating cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients.PET Molecular Targets and Near-Infrared Fluorescence Imaging of Atherosclerosis.Active Site Mapping of Human Cathepsin F with Dipeptide Nitrile Inhibitors.Degradation of apolipoprotein B-100 by lysosomal cysteine cathepsins.Enzyme-modified non-oxidized LDL (ELDL) induces human coronary artery smooth muscle cell transformation to a migratory and osteoblast-like phenotype
P2860
Q27693906-9E42A180-7A3A-4E6E-AB8A-E924E8A50A6DQ28570792-7CD0205A-5067-45F0-82E0-08F713CDEE77Q30477117-67475616-E6E0-44A6-B4F9-DFE32753174EQ33822554-112DDE22-9FD7-4069-B332-47FF9074C682Q33901989-8EB2BB9C-9B75-4E79-960C-8B4B8EB52CDBQ34598912-7D1020E5-765A-42BA-AABA-991AA986E743Q34618287-4EF6AB92-7675-436F-B3ED-38AFECCA6B79Q34770283-7FA99364-E5C8-4AA3-822C-EA152B737339Q35098737-B5B4A0BC-1F37-4CA0-8F58-B7C18C367D1DQ35309535-50EC8B9B-6D46-47B5-9175-65FEC4C3B6D8Q35883165-B827B1F4-22B5-49F7-9F12-5FDFCEF20F3DQ36940618-34F9AD82-D6A1-4DD2-A26B-F30E442E3361Q37401560-D60634F1-D2E4-46AB-B179-9BAE5003DEA3Q38162775-09BAE3CC-2E9A-42A2-836C-9D0E04A7BAD1Q38271332-8BA6D3F4-DB39-4DA3-ACE6-769E1E7B97E7Q38756684-681E35CC-91AE-43BC-AC52-C3E611C6F488Q40171398-624758F9-01A6-4B55-9726-25D55D65C46FQ41088013-351C8120-B21D-448F-A318-B179BC105CD5Q41530349-3F8F61FC-3460-4139-B5EB-9B21ACCEF73EQ42072325-258D1F73-1316-44D4-A102-E9106AC7E020Q46312965-587AADA2-7E36-43C2-8D47-2643E3C0A4A0Q46686104-DBE1DBA1-922B-4C13-A835-44AD358D3103Q46691122-116D19B7-67D8-4374-AE60-209DEA58994FQ47696129-C8BB8CCC-AEC8-452B-BDFA-078E38A0D7E4Q48588869-731481BB-B284-4F2C-AE09-8DF632E0C03CQ50051033-B642A1D3-8F0C-4FE1-842E-EABFEA79BCEBQ52934515-54B85A8A-2059-4C86-8F41-F33EEECBFC76Q53599405-092BCAE0-2F50-403D-ADDC-63D2982EBD60Q58790794-C76A2F6A-7793-4474-86C0-D32778608951
P2860
Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Cysteine protease cathepsin F ...... ipoprotein particles in vitro.
@ast
Cysteine protease cathepsin F ...... ipoprotein particles in vitro.
@en
Cysteine protease cathepsin F ...... ipoprotein particles in vitro.
@nl
type
label
Cysteine protease cathepsin F ...... ipoprotein particles in vitro.
@ast
Cysteine protease cathepsin F ...... ipoprotein particles in vitro.
@en
Cysteine protease cathepsin F ...... ipoprotein particles in vitro.
@nl
prefLabel
Cysteine protease cathepsin F ...... ipoprotein particles in vitro.
@ast
Cysteine protease cathepsin F ...... ipoprotein particles in vitro.
@en
Cysteine protease cathepsin F ...... ipoprotein particles in vitro.
@nl
P2093
P356
P1476
Cysteine protease cathepsin F ...... lipoprotein particles in vitro
@en
P2093
Dieter Brömme
Helena Aitio
Ken A Lindstedt
Markku O Pentikäinen
Petri T Kovanen
P304
34776-34784
P356
10.1074/JBC.M310814200
P407
P577
2004-06-07T00:00:00Z